| scholarly article | Q13442814 |
| P2093 | author name string | Robert C Baxter | |
| Nick Pavlakis | |||
| Ross C Smith | |||
| Matthew H Wong | |||
| Aiqun Xue | |||
| P2860 | cites work | Cyr61/CCN1 signaling is critical for epithelial-mesenchymal transition and stemness and promotes pancreatic carcinogenesis | Q21245763 |
| mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E | Q24301780 | ||
| Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes | Q24595981 | ||
| Distant metastasis occurs late during the genetic evolution of pancreatic cancer | Q24624284 | ||
| A complex interplay between Akt, TSC2 and the two mTOR complexes | Q24655791 | ||
| Genetic alterations in pancreatic carcinoma | Q24801465 | ||
| Upstream and downstream of mTOR | Q28277365 | ||
| The causes and consequences of genetic heterogeneity in cancer evolution | Q29615848 | ||
| Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer | Q29618155 | ||
| Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group | Q29619344 | ||
| Inhibition of PI3K/AKT and MAPK/ERK pathways causes activation of FOXO transcription factor, leading to cell cycle arrest and apoptosis in pancreatic cancer | Q34043823 | ||
| Oncogenic KRAS signalling in pancreatic cancer | Q34113460 | ||
| RAS/ERK modulates TGFbeta-regulated PTEN expression in human pancreatic adenocarcinoma cells | Q34117879 | ||
| Pancreatic cancer biology and genetics | Q35013204 | ||
| PI3K/PTEN/AKT pathway. A critical mediator of oncogenic signaling | Q35076033 | ||
| Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health | Q35679353 | ||
| PI3K/Akt signalling pathway and cancer. | Q35692250 | ||
| Cotargeting MAPK and PI3K signaling with concurrent radiotherapy as a strategy for the treatment of pancreatic cancer | Q35951620 | ||
| Molecular targeted approaches for treatment of pancreatic cancer. | Q36174910 | ||
| Molecular mechanisms of pancreatic carcinogenesis. | Q36347882 | ||
| Smad4-independent TGF-beta signaling in tumor cell migration | Q36857815 | ||
| Cooperative activation of PI3K by Ras and Rho family small GTPases | Q37058907 | ||
| Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer | Q37376100 | ||
| Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. | Q37865381 | ||
| PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types | Q38084846 | ||
| Targeting the PI3K/Akt/mTOR pathway in malignancy: rationale and clinical outlook | Q38190918 | ||
| Mutant K-Ras increases GSK-3β gene expression via an ETS-p300 transcriptional complex in pancreatic cancer | Q38262388 | ||
| SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial | Q38385490 | ||
| miR-218 inhibits the invasion and migration of colon cancer cells by targeting the PI3K/Akt/mTOR signaling pathway | Q38901103 | ||
| Optimization of the tetrazolium dye (MTT) colorimetric assay for cellular growth and viability | Q39592755 | ||
| Key role of phosphoinositide 3-kinase class IB in pancreatic cancer | Q39650716 | ||
| Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab | Q39840667 | ||
| CCL5 increases lung cancer migration via PI3K, Akt and NF-kappaB pathways | Q39906605 | ||
| Human equilibrative nucleoside transporter 1 expression analysed by the clone SP 120 rabbit antibody is not predictive in patients with pancreatic cancer treated with adjuvant gemcitabine - Results from the CONKO-001 trial | Q41689546 | ||
| Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3. | Q42914090 | ||
| Mammalian target of rapamycin (mTOR): pro- and anti-apoptotic | Q43882655 | ||
| Inhibition of the phosphatidylinositol 3'-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo | Q44248593 | ||
| Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial | Q44299542 | ||
| Selective requirement of PI3K/PDK1 signaling for Kras oncogene-driven pancreatic cell plasticity and cancer | Q45339155 | ||
| Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma. | Q53044984 | ||
| Fitting models for the joint action of two drugs using SAS | Q81544627 | ||
| P433 | issue | 7 | |
| P921 | main subject | adenocarcinoma | Q356033 |
| P304 | page(s) | 425-435 | |
| P577 | publication date | 2016-07-01 | |
| P1433 | published in | Neoplasia | Q2962042 |
| P1476 | title | Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal Adenocarcinoma | |
| P478 | volume | 18 |
| Q38742105 | Challenging of AS160/TBC1D4 Alters Intracellular Lipid milieu in L6 Myotubes Incubated With Palmitate. |
| Q64268219 | Curcumin regulates the miR-21/PTEN/Akt pathway and acts in synergy with PD98059 to induce apoptosis of human gastric cancer MGC-803 cells |
| Q44318431 | Developing a novel dual PI3K-mTOR inhibitor from the prodrug of a metabolite |
| Q64113876 | Ginsenoside Rg5 induces apoptosis in human esophageal cancer cells through the phosphoinositide‑3 kinase/protein kinase B signaling pathway |
| Q33623582 | Growth and stress response mechanisms underlying post-feeding regenerative organ growth in the Burmese python |
| Q58751858 | HDAC6 inhibitor TST strengthens the antiproliferative effects of PI3K/mTOR inhibitor BEZ235 in breast cancer cells via suppressing RTK activation |
| Q64059795 | KLF5 regulated lncRNA RP1 promotes the growth and metastasis of breast cancer via repressing p27kip1 translation |
| Q41471129 | MEK inhibitors cobimetinib and trametinib, regressed a gemcitabine-resistant pancreatic-cancer patient-derived orthotopic xenograft (PDOX) |
| Q37736706 | Noninvasive Bioluminescence Imaging of AKT Kinase Activity in Subcutaneous and Orthotopic NSCLC Xenografts: Correlation of AKT Activity with Tumor Growth Kinetics |
| Q37569554 | Phospho-Akt overexpression is prognostic and can be used to tailor the synergistic interaction of Akt inhibitors with gemcitabine in pancreatic cancer |
| Q37447349 | Suppression of Tumor Growth and Muscle Wasting in a Transgenic Mouse Model of Pancreatic Cancer by the Novel Histone Deacetylase Inhibitor AR-42. |
| Q50130156 | The antitumor natural product tanshinone IIA inhibits protein kinase C and acts synergistically with 17-AAG. |
| Q58599229 | Urolithin A, a novel natural compound to target PI3K/AKT/mTOR pathway in pancreatic cancer |
Search more.